NCT05673304 Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
| NCT ID | NCT05673304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-05-24 |
| Primary Completion | 2027-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC). As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.
Eligibility Criteria
Inclusion Criteria: * Luminal B-like BC, cT1-2 * Indication for neoadjuvant chemotherapy Exclusion Criteria: * Pregnancy * Breast feeding * Patient not available for follow up
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.